공시 • Mar 05
Matricelf Ltd. Reports Positive RNA Sequencing Results Demonstrating Promising Safety Profile Of Its Personalized Spinal Cord Implant Matricelf Ltd. announced positive results from advanced RNA sequencing analyses of its human tissue implant, supporting key safety characteristics required for progression toward clinical trials. The analyses were conducted as part of a comprehensive safety characterization program aligned with international regulatory standards, including requirements of the US FDA. Matricelf performed advanced genetic testing using single nucleus RNA sequencing technology seq snRNA on 4 separate implant batches to enable deep characterization of the cellular composition of its proprietary engineered neural tissue implant. The findings support that all cell populations within the implant are in a post mitotic state, meaning there was no evidence of proliferative or dividing cells. The results indicate normal developmental progression of the engineered tissue and demonstrate that the cells have reached a stable stage of differentiation without continued cell division. Importantly, the absence of proliferating cells significantly reduces potential risks such as uncontrolled cell growth or formation of unintended tissue, key considerations in the development of advanced cell based therapies. Matricelf is developing an autologous engineered neural tissue implant for patients suffering from paralysis due to spinal cord injury. The implant consists of both cellular and extracellular components derived from the patient's own body. The cellular component is generated from a blood sample collected from the patient, from which induced pluripotent stem cells iPSCs are produced. In parallel, an omentum tissue sample, a fatty tissue surrounding abdominal organs, is harvested to create a proprietary hydrogel serving as the extracellular scaffold. Using Matricelf's proprietary tissue engineering process, the cellular and extracellular components are combined to create a personalized engineered neural tissue implant intended to repair the patient's injured spinal cord. The positive RNA sequencing results represent an important milestone in the company's regulatory and clinical development pathway as it prepares for advanced preclinical studies and future human clinical trials. 공시 • Feb 27
Matricelf Ltd Appoints Ron Mayron as Active Chairman of the Board of Directors Matricelf Ltd. announced the appointment of Mr. Ron Mayron as Active Chairman of the Board of Directors. Mr. Mayron's appointment follows shareholder approval and submission of his formal Director Eligibility Declaration in accordance with the Israeli Companies Law. Mr. Mayron holds a BSc in Industrial Engineering and Management from Ben Gurion University and an MBA from Tel Aviv University. He has served as CEO and owner of RonMed Ltd. since 2015 and brings decades of executive leadership experience in the healthcare and life sciences sectors. Over the past 5 years, Mr. Mayron has served as a director in multiple public and private life sciences companies, including SimpliVity, InnoCan Pharma, IceCure Medical, BioLight, G Medical, Kadimastem, Entera Bio, DNA Biomedical Solutions, and Earmada . His broad board level experience spans biotechnology, medical devices, pharmaceuticals, and advanced therapeutic platforms. In his eligibility declaration, Mr. Mayron confirmed that he meets the statutory qualifications to serve as a director of a public company under Israeli law and that he is not classified as a director with accounting and financial expertise. He also confirmed that he does not hold shares or convertible securities of the Company at the time of appointment. New Risk • Feb 19
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2025. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪15m free cash flow). Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 12% per year over the past 5 years. Shareholders have been substantially diluted in the past year (81% increase in shares outstanding). Revenue is less than US$1m. Minor Risks Latest financial reports are more than 6 months old (reported June 2025 fiscal period end). Market cap is less than US$100m (₪146.3m market cap, or US$46.5m). New Risk • Dec 23
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 71% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪15m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 15% per year over the past 5 years. Shareholders have been substantially diluted in the past year (71% increase in shares outstanding). Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (₪153.5m market cap, or US$48.2m). New Risk • Aug 18
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Israeli stocks, typically moving 10% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪15m free cash flow). Share price has been highly volatile over the past 3 months (10% average weekly change). Earnings have declined by 15% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Market cap is less than US$100m (₪42.8m market cap, or US$12.7m). New Risk • Aug 12
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: ₪34.2m (US$9.98m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₪12m free cash flow). Earnings have declined by 26% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (₪34.2m market cap, or US$9.98m). Minor Risk Share price has been volatile over the past 3 months (7.3% average weekly change). 